Mark Cuban Urges Trump to Remove FDA Fees to Boost USA Generics Manufacturing
Billionaire entrepreneur Mark Cuban has urged Donald Trump’s administration to scrap the high regulatory fees charged by the USA Food and Drug Administration (FDA) for generic drug approvals.
Regulation | 06/12/2025 | By Darshana | 212
Ipca Labs Receives US FDA Form 483 with Three Observations after Tarapur Facility Inspection
The US Food and Drug Administration (US FDA) has completed an inspection of Ipca Laboratories' Active Pharmaceutical Ingredients (APIs) manufacturing plant in Tarapur, Palghar (Maharashtra).
Regulation | 06/12/2025 | By Dineshwori | 898
Lupin Receives Tentative US FDA Nod for Siponimod Tablets, Generic to Novartis' Mayzent
Lupin has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Siponimod Tablets in strengths of 0.25 mg, 1 mg and 2 mg.
Regulation | 05/12/2025 | By Dineshwori | 612
FDA Lifts Partial Clinical Hold on Vanda's Tradipitant for Motion Sickness
The lift allows Vanda to extend clinical studies of tradipitant in motion sickness. Meanwhile, the review of the fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track.
Regulation | 05/12/2025 | By Dineshwori | 451
FDA Approves Expanded Use of Eli Lilly's Jaypirca in Relapsed or Refractory CLL/SLL
Eli Lilly’s Jaypirca (pirtobrutinib) is the only medicine in CLL or SLL that has been prospectively studied in a randomised trial of patients previously treated with a covalent BTK inhibitor.
Regulation | 04/12/2025 | By Dineshwori | 263
NPPA Fixes Retail Prices for 11 Drug Formulations Under DPCO 2013
The National Pharmaceutical Pricing Authority (NPPA) has issued a fresh notification fixing retail prices for multiple essential drug formulations—including antihypertensives, antibiotics, antidiabetics, and paediatric syrups—under the Drugs (Prices Control) Order, 2013. The revised prices apply to approved manufacturers and exclude GST.
Regulation | 02/12/2025 | By Dineshwori | 266
Biocomposites Gains Expanded Approval in India for STIMULAN Rapid Cure
According to Biocomposites, India is the first country in the world to approve STIMULAN Rapid Cure to be mixed with antifungals.
Regulation | 01/12/2025 | By Dineshwori | 265
Dr. Reddy's Wins European Approval for Denosumab Biosimilar
Dr. Reddy’s Laboratories has received approval from the European Commission for its denosumab biosimilar, used in the treatment of osteoporosis and cancer-related bone conditions.
Regulation | 25/11/2025 | By Darshana | 226
Ocuvex Resubmits CRL to FDA for PDP-716 NDA, SPARC Reveals
Sun Pharma Advanced Research Company (SPARC) announced that Ocuvex Therapeutics has resubmitted a Complete Response Letter (CRL) to the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of PDP-716.
Regulation | 20/11/2025 | By Dineshwori | 526
Biocon Pharma Receives US FDA Nod for Tofacitinib Extended-Release Tablets
Biocon Pharma has received approval from the US Food and Drug Administration (US FDA) for its ANDA for tofacitinib extended-release tablets, securing final approval for the 11 mg strength and tentative approval for the 22 mg strength.
Regulation | 19/11/2025 | By Dineshwori | 346
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy